< Back to Portfolio

10X Genomics

Changing the definition of sequencing.

  • company-website-icon
  • company-linkedin-icon
  • company-twitter-icon

About

10X Genomics is changing the definition of sequencing by providing an innovative genomics platform that dramatically upgrades the capabilities of existing short read sequencers. The company does this through a combination of elegant microfluidics, chemistry, and bioinformatics. With the GemCode Platform, researchers can now find structural variants, haplotypes, and other valuable long range information while leveraging existing sequencing workflows.

  • Location: Pleasanton, CA
  • Paladin Initial Investment Date: November 2011

Our Co-Investor Partners

Portfolio Stats

Over 65 Companies

Paladin has invested in over 65 portfolio companies since 2001.

4 Continents

Paladin has invested in companies in North America, Australia, Europe, and South America.

Over $1 billion

Paladin manages over $1 billion of committed capital across multiple funds and investment vehicles.